Health Canada approves SCENESSE® for erythropoietic protoporphyria treatment in Canada
Executive summary: Health Canada granted a Notice of Compliance for SCENESSE® (afamelanotide) to treat erythropoietic protoporphyria (EPP), allowing the drug to be marketed in Canada. Provides the first approved therapy for EPP in Canada, addressing a rare, debilitating photosensitivity disorder and creating a new revenue stream for Clinuvel Pharmaceuticals.
Who is involved: Health Canada, Clinuvel Pharmaceuticals (the developer of SCENESSE®), patients diagnosed with EPP, and Canadian provincial health agencies responsible for drug reimbursement.
Likely next: Provincial formularies will review SCENESSE® for reimbursement inclusion, with potential launch and commercial rollout in Canada during the second half of 2026.
Health Canada's issuance of a Notice of Compliance for SCENESSE® marks the first regulatory approval of the drug for erythropoietic protoporphyria (EPP) in the country, addressing a significant unmet medical need for patients with this rare metabolic disorder. The approval enables Clinuvel Pharmaceuticals to market and distribute SCENESSE® across Canadian provinces, pending provincial reimbursement decisions. This development underscores Canada's ongoing commitment to facilitating access to orphan therapies through its regulatory pathways.
Timeline
- — SCENESSE® approved for EPP in Canada (GlobeNewswire)
Analysis — what this means
Sectors affected
- Orphan drug pharmaceuticals
- Rare disease treatment
- Canadian healthcare market
Historical parallels
- Health Canada's July 9, 2026 favorable reimbursement recommendation for EMPAVELI (pegcetacoplan) in the treatment of C3G and IC-MPGN
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped